Status:
ACTIVE_NOT_RECRUITING
Safe and Timely Cessation of Isolation of Patients With COVID-19 (The SCIP-COVID-19) Study
Lead Sponsor:
Anne Voor in 't holt
Collaborating Sponsors:
Maasstad Hospital
Medisch Spectrum Twente
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: In the treatment, care and isolation of COVID-19 patients, one of the most important issues is determining the duration of infectiousness. The current Dutch guideline advises at least 14 d...
Detailed Description
Rationale: In the treatment, care and isolation of COVID-19 patients, one of the most important issues is determining the duration of infectiousness. The current Dutch guideline advises at least 14 d...
Eligibility Criteria
Inclusion
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Admission for COVID-19 and tested positive between the end of February 2020 and December 1st 2021.
- Admission for other reasons than COVID-19, but during hospital stay detected with COVID-19.
- Patients ≥18 years old.
Exclusion
- A potential subject who meets any of the following criteria will be excluded:
- Adult patients with registered opt-out for using clinical and/or laboratory data.
- Patients \<18 years old.
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
7000 Patients enrolled
Trial Details
Trial ID
NCT05346042
Start Date
December 1 2022
End Date
December 31 2025
Last Update
March 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus Medical Center
Rotterdam, South Holland, Netherlands, 3000 CA